Research Article, J Virol Antivir Res Vol: 4 Issue: 1
Role of Interleukin-10, Interleukin-12 in the Response Prediction during Combined PEG Interferon-alpha 2a and Ribavirin Therapy in Patients with Chronic Hepatitis C
|Amal Ahmed Mohamed1*, Marwa M E Abd Elmonsef2, Marwa K. Darwish3, Mohamed A Atallah4, Mohamed Ezz5, Said El-Feky6 and Heba Ebrahim7|
|1Biochemistry Department, National Hepatology and Tropical Medicine Research Institute, Egypt|
|2Microbiology and Immunology Department, Faculty of Medicine, Tanta University, Egypt|
|3Biochemistry Department, Faculty of Science, Suez University, Egypt|
|4Tropical Department, National Hepatology and Tropical Medicine Research Institute, Egypt|
|5Department of Hepatology and Gastroenterology, Ahmed Maher Teaching Hospital, Egypt|
|6Department of Biochemistry, Damanhur National Medical Institute, Egypt|
|7Biochemistry of Department, National Institute of Diabetes and Endocrinology, Egypt|
|Corresponding author : Amal Ahmed Mohamed
Consultant of Biochemistry and Molecular Biology, Biochemistry department, National Hepatology and Tropical Medicine Research Institute, Fom El-Khalig, Cairo,11796, Egypt
|Received: August 08, 2014 Accepted: January 12, 2015 Published: January 20, 2015|
|Citation: Ahmed AM, Abd El Monsef MME, Darwish MK, Atallah MA, Ezz MD, et al. (2015) Role of Interleukin-10, Interleukin-12 in the Response Prediction during Combined PEG-Interferon-alpha 2a and Ribavirin Therapy in Patients with Chronic Hepatitis C. J Virol Antivir Res 4:1. doi:10.4172/2324-8955.1000134|
Background: Egypt has the highest prevalence of adult HCV infection in the world, averaging 15%-25% in rural communities. Sustained virological response in genotype 4 Egyptian patients treated with PEG-IFN alfa-2a and ribavirin was estimated around 60%. It is of major interest for both patient care and economic approach to predict failure of response. Several factors have been shown to influence response to antiviral treatment. Cytokines play an important role in the pathogenesis, progression and treatment outcome of HCV infection.
Aim: The current study was designated to assess serum interleukin-10 and interleukin-12 levels in CHC genotype 4 patients and investigate their benefit as predictors of antiviral response.
Methods: This study was conducted on a total number of 70 participants admitted to Hepatology and Gastroenterology Department in NHTMRI (National Hepatology & Tropical Medicine Research Institute). The participants of this study were divided into two groups as following; Group I: 20 healthy subjects (as controls), while the cases in Group II: 50 patients with chronic hepatitis C (CHC) genotype 4. Results: Our results showed that IL-12 and IL-10 levels were higher in patients with HCV infection than in control participants and were significantly higher in the group of the sustained responders, compared with non-responders. Serum IL-10 level showed a sensitivity and specificity of 76.7% and 73.3% respectively while serum IL-12 level showed sensitivity and specificity of 90% and 75% respectively.
Conclusion: These results demonstrate the beneficial role ofIL-10, IL-12 in achieving an SVR during IFN-alpha and ribavirin therapy